Pfizer gets FDA nod for Vyndaqel and Vyndamax to treat transthyretin amyloid cardiomyopathy

This article was originally published here

The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

The post Pfizer gets FDA nod for Vyndaqel and Vyndamax to treat transthyretin amyloid cardiomyopathy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply